GlassScriptPhysician profile
Mohammad I Chaudry
NPI 1679518492
$878,076.63
in general payments reported to CMS, 2019-2025
19 companies · $102K in 2025
The $102K reported for 2025 was more than what 98% of Neuroradiology providers received nationally (typical 2025 total: $278).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $79K · 2020: $79K · 2021: $178K · 2022: $234K · 2023: $110K · 2024: $97K · 2025: $102K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $236K · Consulting Fee: $38K · Travel and Lodging: $19K · Food and Beverage: $16K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $236,060.62 |
| Consulting Fee | $37,672.29 |
| Travel and Lodging | $18,593.97 |
| Food and Beverage | $15,834.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Microvention, INC. | $340,058.61 | 2019-2025 | Web Aneurysm Embolization System, Stent, Sofia 6f-131cm Str |
| Medtronic, INC. | $215,297.21 | 2021-2025 | Pipeline, Intellis Adaptivestim, Kyphon Express II Kyphopak Tray |
| Medical Device Business Services, INC. | $131,122.89 | 2019-2025 | Embotrap, Spotlight, Embotrap |
| Imperative Care, INC | $87,797.67 | 2019-2025 | Zoom 88-T Large Distal Platform, Zoom Reperfusion Catheter, Symphony Catheter |
| Siemens Medical Solutions USA, INC. | $62,290.51 | 2019-2023 | Artis Icono Biplane, Corpath Imaging System |
| Penumbra, INC. | $18,572.05 | 2019-2025 | Smart Coil, Penumbra Coil 400, Penumbra System |
| Medtronic USA, INC. | $10,730.68 | 2019-2020 | |
| Qapel Medical INC | $5,770.32 | 2022-2025 | |
| Depuy Synthes Sales INC. | $2,351.37 | 2019-2025 | Cerepak Uniform, N/A, Embotrap |
| Stryker Corporation | $1,490.28 | 2019-2025 | Na, Evolve, Surpass Evolve |
| Corindus INC. | $1,280.28 | 2019 | |
| Rapid Medical LTD | $349.37 | 2021-2025 | Comaneci 17, Tigertriever 17 Revascularization Device |
| Route 92 Medical, INC. | $307.81 | 2024-2025 | 8f Base Camp Sheath System |
| Maduro Medical, INC. | $255.85 | 2025 | |
| Vasorum USA INC. | $160.93 | 2023 | Celt Acd |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Brainlab, INC. | $103.16 | 2019 | |
| Balt USA, LLC | $81.59 | 2020-2021 | |
| Boston Scientific Corporation | $30.33 | 2025 | Cds - Mct/Cem Monitoring |
| Arbor Pharmaceuticals, INC. | $25.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$149,625.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Chaudry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.